Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial
Open Access
- 13 October 2023
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (4) , 681-689
Abstract
Hippocampal hyperactivity is a novel pharmacological target in the treatment of schizophrenia. We hypothesized that levetiracetam (LEV), a drug binding to the synaptic vesicle glycoprotein 2 A, normalizes hippocampal activity in persons with schizophrenia and can be measured using neuroimaging methods. Thirty healthy control participants and 30 patients with schizophrenia (28 treated with antipsychotic drugs), were randomly assigned to a double-blind, cross-over trial to receive a single administration of 500 mg oral LEV or placebo during two study visits. At each visit, we assessed hippocampal function using resting state fractional amplitude of low frequency fluctuations (fALFF), cerebral blood flow (CBF) with arterial spin labeling, and hippocampal blood-oxygen-level-dependent (BOLD) signal during a scene processing task. After placebo treatment, we found significant elevations in hippocampal fALFF in patients with schizophrenia, consistent with hippocampal hyperactivity. Additionally, hippocampal fALFF in patients with schizophrenia after LEV treatment did not significantly differ from healthy control participants receiving placebo, suggesting that LEV may normalize hippocampal hyperactivity. In contrast to our fALFF findings, we did not detect significant group differences or an effect of LEV treatment on hippocampal CBF. In the context of no significant group difference in BOLD signal, we found that hippocampal recruitment during scene processing is enhanced by LEV more significantly in schizophrenia. We conclude that pharmacological modulation of hippocampal hyperactivity in schizophrenia can be studied with some neuroimaging methods, but not others. Additional studies in different cohorts, employing alternate neuroimaging methods and study designs, are needed to establish levetiracetam as a treatment for schizophrenia.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (F30-MH125507, R01-MH70560)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32-GM007347)
- U.S. Department of Health & Human Services | National Institutes of Health (UL1-TR000445)
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
This publication has 74 references indexed in Scilit:
- Neural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for PsychosisSchizophrenia Bulletin, 2012
- Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive ImpairmentNeuron, 2012
- Arterial Spin Labeling (ASL) fMRI: Advantages, Theoretical Constrains and Experimental Challenges in NeurosciencesInternational Journal of Biomedical Imaging, 2012
- Anatomical and functional correlates of human hippocampal volume asymmetryPsychiatry Research: Neuroimaging, 2012
- Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRIPsychiatry Research: Neuroimaging, 2011
- Amplitude of low-frequency oscillations in schizophrenia: A resting state fMRI studySchizophrenia Research, 2010
- Differential Targeting of the CA1 Subfield of the Hippocampal Formation by Schizophrenia and Related Psychotic DisordersArchives of General Psychiatry, 2009
- The Cognitive Neuroscience of Memory Function and Dysfunction in SchizophreniaBiological Psychiatry, 2008
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends in Neurosciences, 2008
- Cortical Surface-Based AnalysisNeuroImage, 1999